Alterity Therapeutics Ltd (ATHE)vsJohnson & Johnson (JNJ)
ATHE
Alterity Therapeutics Ltd
$4.02
-2.52%
HEALTHCARE · Cap: $88.31M
JNJ
Johnson & Johnson
$225.33
+0.16%
HEALTHCARE · Cap: $554.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 1451922% more annual revenue ($96.36B vs $6.64M). JNJ leads profitability with a 21.8% profit margin vs -219.9%. JNJ earns a higher WallStSmart Score of 59/100 (C).
ATHE
Avoid26
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ATHE.
Margin of Safety
-70.6%
Fair Value
$135.54
Current Price
$225.33
$89.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 74.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -46.4% — below average capital efficiency
Distress zone — elevated risk
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ATHE
The strongest argument for ATHE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 74.6% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : ATHE
The primary concerns for ATHE are EPS Growth, Market Cap, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ATHE profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
ATHE is growing revenue faster at 74.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (59/100 vs 26/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alterity Therapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?